Saturday, December 8 - Scientific Presentations


OncoLink Booth 264 at ASH 2001.

Analysis of Predisposing Factors for Hepatic Veno-Occlusive Disease after Treatment with Gemtuzumab Ozogamicin (Mylotargr, CMA-676).
Candidate Gene Targets of the c-Myb Protooncogene in Human Myloid Leukemia
Inter-Institutional Second Opinion Pathologic Review of Lymphoproliferative Disorders After WHO Classification.
Low Penetration of Imatinib (STI571) into the CSF Indicates the Need for Standard CSF Prophylaxis in Patients with CML Lymphoid Blast Crisis and Philadelphia Chromosome Positive ALL
Novel Erythropoeisis Stimulating Protein (Aranesp) Enhances Pegylated Soluble Tumor Necrosis Factor Receptor Type 1 (PEG sTNF-R1) Alleviation of Anemia of Chronic Disease (ACD) in a Rodent Model of Systemic Inflammation.
Positron Emission Tomography with 18F-FDG in the Evaluation of Post-Treatment Residual Mass in Patients with Malignant Lymphoma.
STI-571 in the Treatment of Children with Philadelphia (Ph+) Chromosome-Positive Leukemia: Results from a Children's Oncology Group (COG) Phase I Study.
Study of Bone Marrow Involvement in 1161 Consecutive Hodgkin's Lymphoma Patients.
Utility of 18-FDG-PET Scanning in Lymphoma by WHO Classification

News
ASH: Second-Line Drugs Target Chronic Myeloid Leukemia

Sep 22, 2014 - In patients with drug-resistant chronic myeloid leukemia, two second-line drugs -- nilotinib and dasatinib -- may be at least as effective as the front-line drug imatinib, according to research presented this week at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More